Zobrazeno 1 - 10
of 78
pro vyhledávání: '"Jane S. Lebkowski"'
Autor:
Mohamed A. Faynus, Jeffrey K. Bailey, Britney O. Pennington, Mika Katsura, Duncan A. Proctor, Ashley K. Yeh, Sneha Menon, Dylan G. Choi, Jane S. Lebkowski, Lincoln V. Johnson, Dennis O. Clegg
Publikováno v:
Bioengineering, Vol 9, Iss 7, p 297 (2022)
Dry age-related macular degeneration (AMD) is estimated to impact nearly 300 million individuals globally by 2040. While no treatment options are currently available, multiple clinical trials investigating retinal pigmented epithelial cells derived f
Externí odkaz:
https://doaj.org/article/5f35764a0d304571b157eef32c3eac10
Autor:
Stephen L. McKenna, Reza Ehsanian, Charles Y. Liu, Gary K. Steinberg, Linda Jones, Jane S. Lebkowski, Edward Wirth, Richard G. Fessler
Publikováno v:
Journal of Neurosurgery: Spine. 37:321-330
OBJECTIVE The purpose of this study was to evaluate the safety of oligodendrocyte progenitor cells (LCTOPC1) derived from human pluripotent stem cells administered between 7 and 14 days postinjury to patients with T3 to T11 neurologically complete sp
Autor:
Richard G. Fessler, Reza Ehsanian, Charles Y. Liu, Gary K. Steinberg, Linda Jones, Jane S. Lebkowski, Edward D. Wirth, Stephen L. McKenna
Publikováno v:
Journal of neurosurgery. Spine. 37(6)
OBJECTIVE The primary objective of this study was to evaluate the safety of 3 escalating doses of oligodendrocyte progenitor cells (LCTOPC1; previously known as GRNOPC1 and AST-OPC1) administered at a single time point between 21 and 42 days postinju
Autor:
Richard G. Fessler, R David Fessler, Charles Y. Liu, Edward D. Wirth, Catherine A. Priest, Stephen McKenna, Jane S. Lebkowski
Publikováno v:
Journal of neurosurgery. Spine.
OBJECTIVE This study was conducted as a final proof-of-safety direct injection of oligodendrocyte progenitor cells into the uninjured spinal cord prior to translation to the human clinical trials. METHODS In this study, 107 oligodendrocyte progenitor
Publikováno v:
Stem Cells Translational Medicine
Cervical spinal cord injury (SCI) remains an important research focus for regenerative medicine given the potential for severe functional deficits and the current lack of treatment options to augment neurological recovery. We recently reported the pr
Autor:
Casey C. Case, Kevin Nishimoto, Edward D. Wirth, Debasish Sen, Jane S. Lebkowski, William Blum, Laurence Elias, Hanna Jean Khoury, Patrick S. Stiff, Anita Reddy, John F. DiPersio, Robert H. Collins
Publikováno v:
Cancer. 123:3061-3072
BACKGROUND Telomerase activity in leukemic blasts frequently is increased among patients with high-risk acute myeloid leukemia (AML). In the current study, the authors evaluated the feasibility, safety, immunogenicity, and therapeutic potential of hu
Publikováno v:
Regenerative Medicine. 10:939-958
Aim: To characterize the preclinical safety profile of a human embryonic stem cell-derived oligodendrocyte progenitor cell therapy product (AST-OPC1) in support of its use as a treatment for spinal cord injury (SCI). Materials & methods: The phenotyp
Autor:
Hanna J, Khoury, Robert H, Collins, William, Blum, Patrick S, Stiff, Laurence, Elias, Jane S, Lebkowski, Anita, Reddy, Kevin P, Nishimoto, Debasish, Sen, Edward D, Wirth, Casey C, Case, John F, DiPersio
Publikováno v:
Cancer. 123(16)
Telomerase activity in leukemic blasts frequently is increased among patients with high-risk acute myeloid leukemia (AML). In the current study, the authors evaluated the feasibility, safety, immunogenicity, and therapeutic potential of human telomer
Autor:
Kevin Nishimoto, Anita Reddy, Kathryn M. Silk, Jane S. Lebkowski, Su-Yi Tseng, Glenn N Dawes, Herman Waldmann, Anish Sen Majumdar, Paul J. Fairchild
Aim: Dendritic cell (DC)-based vaccines have a potential utility for use in the treatment of malignancy. Human embryonic stem cells (hESCs) may provide a more cost-effective and reliable source of DCs for immunotherapy purposes, providing on-demand a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::22593f171645b99b04fd6c9f852b151b
https://doi.org/10.2217/rme.09.25
https://doi.org/10.2217/rme.09.25
Publikováno v:
Regenerative Medicine. 6:303-318
Aim: Dendritic cell (DC)-based vaccines are designed to exploit the intrinsic capacity of these highly effective antigen presenting cells to prime and boost antigen-specific T-cell immune responses. Successful development of DC-based vaccines will be